ANCO and MOASC are collaborating on a Precision Oncology Symposium 2024 on November 2, 2024 at the Claremont Hotel & Spa.

Precision oncology promises to improve the outcomes of patients through broad molecular diagnostic profiling and individualized treatment recommendations. Recent FDA approvals of new cancer treatments that are based on molecular tumor features and not disease type underscore the relevance of this approach. However, the landscape of available diagnostic technologies and targeted drugs is rapidly changing, making it extremely difficult for practicing oncologists and related professionals to stay up to date and to offer their patients the best molecular diagnostic approach possible. By attending this meeting, clinicians will be informed on cutting edge technologies and their optimal clinical application.

Registration will open in early summer.

Industry Registration

At ANCO we strive to foster meaningful connections and facilitate valuable interactions among participants at our events. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registration for the event is intentionally limited to a maximum of three representatives per company, from companies who are not exhibiting at the event, with a maximum of 20 companies.

Supporters & Exhibitors

Support for ANCO’s & MOASC’s Precision Oncology Symposium 2024 is in part from ANCO’s Sustaining Plus Level Corporate Members: AbbVie, Amgen, AstraZeneca, BeiGene USA, Inc., Bristol-Myers Squibb Oncology, Genmab, Gilead Sciences, Inc., GSK Oncology, Incyte Corporation, Janssen Oncology, Jazz Pharmaceuticals, Inc., Kite, A Gilead Company, Merck & Co., Inc., Mirati Therapeutics, Pfizer Oncology, Pharmacyclics LLC, an AbbVie Company, Regeneron, Stemline, A Menarini Group Company, and Takeda Oncology. And Sustaining Level Corporate Members: Pharma Essentia USA Corporation and SeaGen.